Alkermes Stock Forecast, Price & News

+0.32 (+1.07 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3.28 million shs
Average Volume1.63 million shs
Market Capitalization$4.86 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Alkermes logo

About Alkermes

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.87 out of 5 stars

Medical Sector

692nd out of 1,350 stocks

Pharmaceutical Preparations Industry

333rd out of 664 stocks

Analyst Opinion: 1.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

Is Alkermes a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes
or view top-rated stocks.

What stocks does MarketBeat like better than Alkermes?

Wall Street analysts have given Alkermes a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alkermes wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Alkermes

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) released its quarterly earnings results on Tuesday, July, 27th. The company reported $0.30 EPS for the quarter, topping the Zacks' consensus estimate of $0.12 by $0.18. The business had revenue of $303.72 million for the quarter, compared to analysts' expectations of $277.83 million. Alkermes had a positive trailing twelve-month return on equity of 3.21% and a negative net margin of 5.71%.
View Alkermes' earnings history

How has Alkermes' stock price been impacted by COVID-19?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALKS shares have increased by 85.3% and is now trading at $30.11.
View which stocks have been most impacted by COVID-19

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share (EPS) guidance of $0.520-$0.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.510. The company issued revenue guidance of $1.15 billion-$1.19 billion, compared to the consensus revenue estimate of $1.14 billion.

What price target have analysts set for ALKS?

5 analysts have issued twelve-month price objectives for Alkermes' shares. Their forecasts range from $25.00 to $36.00. On average, they anticipate Alkermes' stock price to reach $28.25 in the next year. This suggests that the stock has a possible downside of 6.2%.
View analysts' price targets for Alkermes
or view top-rated stocks among Wall Street analysts.

Who are Alkermes' key executives?

Alkermes' management team includes the following people:

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes CEO Richard F. Pops on Richard F. Pops has an approval rating of 84% among Alkermes' employees.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (14.16%), Vanguard Group Inc. (10.29%), BlackRock Inc. (8.08%), Sarissa Capital Management LP (7.36%), Primecap Management Co. CA (4.07%) and Renaissance Technologies LLC (3.27%). Company insiders that own Alkermes stock include Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops and Wendy L Dixon.
View institutional ownership trends for Alkermes

Which institutional investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Point72 Asset Management L.P., Credit Suisse AG, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, UBS Asset Management Americas Inc., Russell Investments Group Ltd., and Man Group plc. Company insiders that have sold Alkermes company stock in the last year include Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Richard F Pops, and Wendy L Dixon.
View insider buying and selling activity for Alkermes
or view top insider-selling stocks.

Which institutional investors are buying Alkermes stock?

ALKS stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, BlackRock Inc., Northern Trust Corp, Goldman Sachs Group Inc., Geode Capital Management LLC, Canada Pension Plan Investment Board, Vanguard Group Inc., and Bank of New York Mellon Corp. Company insiders that have bought Alkermes stock in the last two years include Emily Peterson Alva, and Nancy Wysenski.
View insider buying and selling activity for Alkermes
or or view top insider-buying stocks.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $30.11.

How much money does Alkermes make?

Alkermes has a market capitalization of $4.86 billion and generates $1.04 billion in revenue each year. The company earns $-110,860,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does Alkermes have?

Alkermes employs 2,245 workers across the globe.

Does Alkermes have any subsidiaries?

The following companies are subsidiares of Alkermes: Rodin Therapeutics.

When was Alkermes founded?

Alkermes was founded in 1987.

What is Alkermes' official website?

The official website for Alkermes is

Where are Alkermes' headquarters?

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at (531) 772-8000 or via email at [email protected].

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.